CAS 112809-51-5
:Letrozole
Description:
Letrozole is a non-steroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Its mechanism of action involves the inhibition of aromatase, an enzyme responsible for converting androgens into estrogens, thereby reducing estrogen levels in the body. This reduction is crucial as many breast cancers are fueled by estrogen. Letrozole is typically administered orally and is known for its relatively favorable side effect profile compared to other hormonal therapies. Common side effects may include hot flashes, joint pain, fatigue, and potential bone density loss. The chemical structure of letrozole includes a triazole ring, contributing to its pharmacological properties. It is classified under the category of antineoplastic agents and is often part of adjuvant therapy following surgery or as a first-line treatment for advanced breast cancer. Letrozole's efficacy and safety have made it a standard option in breast cancer management, and ongoing research continues to explore its potential in other malignancies and therapeutic contexts.
Formula:C17H11N5
InChI:InChI=1/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
InChI key:InChIKey=HPJKCIUCZWXJDR-UHFFFAOYSA-N
SMILES:C(C1=CC=C(C#N)C=C1)(C2=CC=C(C#N)C=C2)N3C=NC=N3
Synonyms:- 4,4'-(1h-1,2,4-Triazol-1-Ylmethylene) Bis-Benzonitrile
- 4,4'-(1h-1,2,4-Triazol-1-Ylmethylene)Bisbenzonitrile
- 4,4′-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
- 4-[1-(4-Cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile
- Benzonitrile, 4,4′-(1H-1,2,4-triazol-1-ylmethylene)bis-
- Cgs 20267
- Femara
- Lelrozol
- Lerozole
- Letocor
- Letoripe
- Letrazole
- Letrof L Lil
- Letroz
- Letrozol
- Letrozole
- 4,4'-(1H-1,2,4-Triazole-1-ylmethylene)bisbenzonitrile
- Letrozole99%
- CGS-20267, Femara
- letrozolex
- 4,4'-[(1H-1,2,4-Triazole-1-yl)methylene]dibenzonitrile
- 1-[BIS(4-CYANOPHENYL)METHYL]-1,2,4-TRIAZOLE
- See more synonyms
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 16 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Letrozole
CAS:Formula:C17H11N5Purity:>98.0%(HPLC)(T)Color and Shape:White to Light yellow powder to crystalMolecular weight:285.31Letrozole
CAS:Aromatic or modified aromatic drugs with nitrogen hetero-atom(s) only, not elsewhere specified or includedFormula:C17H11N5Color and Shape:White Yellow Crystalline PowderMolecular weight:285.10145Letrozole
CAS:Letrozole (CGS 20267) is an Aromatase Inhibitor. The mechanism of action of letrozole is as an Aromatase Inhibitor.Formula:C17H11N5Purity:98.67% - 99.66%Color and Shape:SolidMolecular weight:285.3027Letrozole
CAS:Applications A nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic.
References Bhatnagar, A.S., et al: J. Steroid Biochem. Mol. Biol., 37, 1021 (1990), Pfister, C.U., et al.: J. Pharm. Sci., 83, 520 (1994), Lipton, A., et al.: Cancer, 75, 2132 (1995),Formula:C17H11N5Color and Shape:NeatMolecular weight:285.3Letrozole
CAS:Formula:C17H11N5Purity:≥ 98.0% (anhydrous basis)Color and Shape:White to off-white powderMolecular weight:285.301-[Bis(4-cyanophenyl)methyl]-1,2,4-triazole
CAS:Purity:97.0%Color and Shape:SolidMolecular weight:285.30999755859375Letrozole - Bio-X ™
CAS:Controlled ProductLetrozole is an aromatase inhibitor drug that is used in the treatment of breast cancer in postmenopausal women. It is a non-steroidal type II inhibitor that blocks the active site and thus blocking the electron transfer chain of CYP19A1. As a result of this, the conversion of androgen to estrogen is inhibited.Formula:C17H11N5Purity:Min. 95%Color and Shape:PowderMolecular weight:285.3 g/molLetrozole
CAS:Controlled ProductNon-steroidal inhibitor of aromataseFormula:C17H11N5Purity:Min. 95%Color and Shape:White PowderMolecular weight:285.3 g/mol
![1-[Bis(4-cyanophenyl)methyl]-1,2,4-triazole](https://static.cymitquimica.com/products/10/thumb/F036495.jpg)
